Genotyping of hepatitis C virus and evaluation of treatment response in Goiânia-Goiás, with emphasis on the polymorphism upstream of IL28B gene

Submitted by Marlene Santos ([email protected]) on 2014-11-27T19:29:54Z No. of bitstreams: 2 Dissertação - Ágabo Macêdo da Costa e Silva- 2014.pdf: 1890977 bytes, checksum: 8a4d7bcee9ab084556c93c3c72e6a9f8 (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)Approved for entry into archive by Cláudia Bueno ([email protected]) on 2014-12-01T14:46:26Z (GMT) No. of bitstreams: 2 Dissertação - Ágabo Macêdo da Costa e Silva- 2014.pdf: 1890977 bytes, checksum: 8a4d7bcee9ab084556c93c3c72e6a9f8 (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5)Made available in DSpace on 2014-12-01T14:46:26Z (GMT). No. of bitstreams: 2 Dissertação - Ágabo Macêdo da Costa e Silva- 2014.pdf: 1890977 bytes, checksum: 8a4d7bcee9ab084556c93c3c72e6a9f8 (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) Previous issue date: 2014-02-28Fundação de Amparo à Pesquisa do Estado de Goiás - FAPEGHepatitis C represents a public health problem worldwide. Hepatitis C virus (HCV) is classified into seven genotypes and many subtypes. Besides their epidemiological importance, these genotypes have influence on the response to hepatitis C treatment, as well as other factors related to the virus and its host, such as polymorphisms upstream of interleukin (IL) 28B locus. Despite the importance of these factors in the response to treatment of hepatitis C, there are no data regarding the subject in the Midwest Region of Brazil. The present study aimed to identify the genotypes of HCV among patients attended at a reference laboratory in Goiânia-GO, and also to assess response to treatment of patients infected with genotype 1 with pegylated interferon (PEG-IFN) and ribavirin (RBV), with emphasis on the polymorphism upstream of IL28B gene (rs 12979860). For HCV genotyping, a cross-sectional study was conduct in an anti-HCV positive patients in a reference laboratory in Goiânia-GO, during in a period of 10 years (2003 to 2012) (n = 1300). From January/2012 to December/2013 (n = 101), a cohort was conduct among patients infected with HCV genotype 1 treated with PEG-IFN and RBV in order to evaluate treatment response. Patients were interviewed and blood samples collected for detection of viral RNA by polymerase chain reaction (PCR) with primers complementary to the region 5’ noncoding (NC) of HCV. All HCV RNA positive samples were genotyped by line probe assay – LiPA, and the samples typed as 1a/1b, 2 and 4 were sequenced in the NS5B region of the viral genome. The analysis of single nucleotide polymorphism (SNP) rs12979860 C/T was performed by restriction fragment length polymorphism (RFLP). Of the 1300 samples tested for HCV RNA, 894 were positive. Among these, genotypes 1 (76.3%), 2 (1.9%), 3 (21.6%) and 4 (0.2%) were found. These data show the predominance of genotype 1, followed by 3 and 2, and support the results of other studies in Goiânia. In addition, genotype 4 was found in the studied population. Regarding to SNP rs12979860 C/T, the TC genotype was the most common (57.4%), followed by CC (23.8%) and TT (18.8%). The rate of sustained virologic response (SVR) was 28.7%, being higher in individuals with the CC genotype (54.2%) when compared to those with CT and TT genotypes (22.4% and 15.8%, respectively). These results indicate that analysis of SNP rs12979860 is an important predictor of SVR following PEG-IFN and RBV treatment in patients infected with HCV genotype 1 in our region.A hepatite C representa um problema de saúde pública mundial. O vírus da hepatite C (HCV) é classificado em sete genótipos e vários subtipos. Além da importância epidemiológica, os genótipos desse vírus influenciam a resposta ao tratamento da hepatite C, assim como outros fatores relacionados ao vírus e ao hospedeiro, como o polimorfismo relacionado ao gene da interleucina (IL) 28B. Apesar da importância desses fatores na resposta ao tratamento da hepatite C, não existem dados sobre o tema na Região Centro-Oeste. O presente estudo teve como objetivos identificar os genótipos do HCV em pacientes atendidos em laboratório de referência em Goiânia-GO e avaliar a resposta ao tratamento com interferon peguilado (PEG IFN) e ribavirina (RBV) em portadores do genótipo 1, com ênfase no polimorfismo relacionado ao gene IL28B (rs 12979860). Foi realizado um estudo de corte transversal para genotipagem do HCV em pacientes anti-HCV reagentes atendidos em laboratório de referência em Goiânia-GO, em um período de 10 anos (2003 a 2012) (n = 1300). Entre janeiro/2012 e dezembro/2013 (n = 101), foi formada uma coorte de portadores do genótipo 1 do HCV submetidos ao tratamento da hepatite C com PEG IFN e RBV, para avaliação de sua resposta. Os pacientes foram entrevistados e amostras sanguíneas coletadas para detecção do RNA viral por reação em cadeia da polimerase (PCR) com iniciadores complementares a região 5’ não codificante (NC) do HCV. Todas as amostras RNAHCV positivas foram genotipadas por line probe assay – LiPA, e as tipadas como 1a/1b, 2 e 4 foram sequenciadas para a região NS5B do genoma viral. A análise do single nucleotide polymorphism (SNP) rs12979860 C/T foi realizada por restriction fragment length polymorphism (RFLP). Das 1300 amostras testadas para RNA-HCV, 894 foram positivas, sendo identificados os genótipos 1 (76,3%), 2 (1,9%), 3 (21,6%) e 4 (0,2%). Estes dados mostram o predomínio do genótipo 1, seguido do 3 e 2, e corroboram os de outros estudos realizados em Goiânia, com a adição do genótipo 4 na população estudada. Em relação ao SNP rs12979860 C/T, o genótipo TC foi o mais frequente (57,4%), seguido por CC (23,8%) e TT (18,8%). A taxa de resposta virológica sustentada (RVS) foi de 28,7%, sendo superior nos portadores do genótipo CC (54,2%) em relação aos genótipos TC e TT (22,4% e 15,8%, respectivamente). Estes resultados indicam que a análise do SNP rs12979860 é importante preditor de RVS ao tratamento com PEG IFN e RBV em pacientes infectados com o genótipo 1 do HCV em nossa região

Epidemiology of hepatitis B virus infection among recyclable waste collectors in central Brazil

Submitted by Luciana Ferreira ([email protected]) on 2018-07-31T13:28:51Z No. of bitstreams: 2 Artigo - Tamíris Augusto Marinho - 2014.pdf: 463246 bytes, checksum: 33b373a77e4444b2ae399c74d3bb1ce7 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Approved for entry into archive by Luciana Ferreira ([email protected]) on 2018-08-01T14:13:26Z (GMT) No. of bitstreams: 2 Artigo - Tamíris Augusto Marinho - 2014.pdf: 463246 bytes, checksum: 33b373a77e4444b2ae399c74d3bb1ce7 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)Made available in DSpace on 2018-08-01T14:13:26Z (GMT). No. of bitstreams: 2 Artigo - Tamíris Augusto Marinho - 2014.pdf: 463246 bytes, checksum: 33b373a77e4444b2ae399c74d3bb1ce7 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2014-02The collection of recyclable waste materials is a widespread activity among the urban poor. Today, this occupation attracts an increasingly large number of individuals. Despite its economic and environmental importance, this activity is associated with unsafe and unhealthy working conditions. The aim of this study was to investigate the seroepidemiological profi le of hepatitis B virus (HBV) infection in a population of recyclable waste collectors in central Brazil. Methods: Recyclable waste collectors from all 15 recycling cooperatives in Goiânia City were invited to participate in the study. The participants (n = 431) were interviewed and screened for hepatitis B surface antigen (HBsAg) and antibodies against HBsAg (anti-HBs) and hepatitis B core antigen (anti-HBc) by enzyme-linked immunosorbent assay (ELISA). HBsAg- and anti-HBc-positive samples were tested for HBV DNA and genotyped. Results: The overall prevalence of HBV infection (HBsAg- and/or anti-HBc-positive) was 12.8%. An age over 40 years and illicit drug use were associated with HBV infection. HBV DNA was detected in 2/3 HBsAg-positive samples and in 1/52 anti-HBc-positive/HBsAg-negative samples (an occult HBV infection rate of 1.9%), in which the genotypes/subgenotypes A/A1, D/D3 and F/F2 were identifi ed. Only 12.3% of the recyclable waste collectors had serological evidence of previous HBV vaccination. Conclusions: These fi ndings highlight the vulnerability of recyclable waste collectors to HBV infection and reinforce the importance of public health policies that address the health and safety of this socially vulnerable population